Nycomed Prepares To Launch First Nonprescription PPI With EU-Wide Approval
This article was originally published in The Tan Sheet
Executive Summary
Nycomed is gearing up to launchPantozol Control (pantoprazole 20 mg) later this year when the firm expects an approval for European Union nonprescription marketing authorization
You may also be interested in...
Oxytrol, Flomax Switches Show Gap Between U.S., U.K. Pathways
EU centralized switch has proven difficult, with only two drugs making the transition from Rx to OTC in the European Medicines Agency process, and EU member state switches also remain complex. Boehringer’s Flomax U.K. switch and Merck’s Oxytrol for Women in the U.S. underscore differences in the regulatory paths.
Oxytrol, Flomax Switches Show Gap Between U.S., U.K. Pathways
EU centralized switch has proven difficult, with only two drugs making the transition from Rx to OTC in the European Medicines Agency process, and EU member state switches also remain complex. Boehringer’s Flomax U.K. switch and Merck’s Oxytrol for Women in the U.S. underscore differences in the regulatory paths.
Japan's Takeda Reportedly Offering $12B For Europe's Nycomed
Japan's largest drug maker, Takeda Pharmaceuticals Co. Ltd., may be close to buying private-equity owned Nycomed AS, based in Switzerland, for about $12 billion